Research-use-only context. This article summarizes published third-party scientific literature and laboratory practice. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. US Prime Peptides products are supplied strictly for in vitro laboratory research and are not for human or veterinary use.
A research peptide can arrive with two documents that both call themselves a certificate of analysis: one from the manufacturer that made the lot and one from a laboratory that had no part in making it. This article explains why those documents are not interchangeable, why two competent laboratories can legitimately report different numbers for the same vial, and how a buyer should weigh each report.
The conflict-of-interest problem in one paragraph
A manufacturer's certificate is a statement by the party that profits from a passing result, produced with the same equipment, reference material and analysts that made the lot. It is not worthless, and in regulated pharmaceutical manufacture it is the primary release document, but it is self-reported. An independent laboratory's report is a statement by a party paid a fixed fee regardless of the outcome, on separate equipment, with its own reference materials and its own procedures. The difference is structural, not a matter of honesty.
The international standard for testing laboratories, ISO/IEC 17025:2017, makes impartiality an explicit requirement: a laboratory must identify risks to its impartiality on an ongoing basis, including those arising from its relationships and from commercial or financial pressures, and must be able to demonstrate how it eliminates or minimizes them. An in-house quality unit can be impartial, but it cannot demonstrate independence from the production organization that employs it. Zolner's 2012 note in the International Journal of Pharmaceutical Compounding adds the other half of the argument: a certificate is needed for every lot, because lot-to-lot variation in chemical materials "can be significant", and a generic or representative certificate tells the reader little about the vial in hand. The anatomy of the document itself is covered in how to read a peptide certificate of analysis.
What a second laboratory adds, and what it does not
A second laboratory adds an independent measurement under an independent method, which is the only way to detect a systematic error in the first. It does not add certainty about anything it did not test. If the independent report covers identity and purity only, the manufacturer's endotoxin and sterility lines remain single-source claims.
| Attribute | Manufacturer certificate | Independent laboratory report |
|---|---|---|
| Who paid, and for what | Internal cost of release | Fixed fee for a result, whatever the result |
| Reference standard | Often the manufacturer's own bulk material | Purchased or in-house standard, value-assigned separately |
| Method | Manufacturer's validated procedure | Laboratory's own procedure; may differ in column, gradient, wavelength |
| Sample tested | Bulk powder before filling, or filled units | Sealed units from the distributed lot |
| Scope | Usually the full release panel | Whatever was ordered; check each line |
| Verifiability | Through the manufacturer | Through the laboratory, by report number |
| Accreditation | May or may not be stated | ISO/IEC 17025 scope can be checked |
The most useful property of the second report is that it tests the sealed, distributed vial rather than the bulk powder. Fill weight errors, moisture uptake during filling, and contamination introduced at fill and finish are invisible in a bulk-powder certificate but visible in a report on finished units. For a research buyer, a lot-matched independent report on finished units is therefore the stronger of the two documents on content, sterility and endotoxin, and at least an equal on identity and purity.
Why two competent laboratories disagree
Two laboratories can report different numbers for the same lot without either being wrong, because "purity" and "content" are method-defined quantities. The largest controlled study of this question for a peptide was run by the USP Biologics Department and reported by Li and colleagues in 2019: multiple laboratories quantified oxytocin by HPLC assay, quantitative NMR and amino acid analysis. HPLC against a shared bulk standard gave the lowest between-laboratory variability, but that coefficient of variation excluded the uncertainty of the standard's own mass-balance purity assignment; qNMR, a direct measurement against an internal standard, was proposed as a primary method worth further exploration. McCarthy and colleagues' 2023 account of USP peptide reference-standard practice describes a two-step value assignment in which bulk material is characterized by mass balance and then used to assign the vialed standard, integrating results from several laboratories and screening for outliers along the way. The scale of the corrections involved is shown by Melanson and colleagues (2018), who measured the TFA counter-ion of an angiotensin II candidate reference material at nearly 25% by mass and combined qNMR, isotope-dilution amino acid analysis and mass balance by a Bayesian approach to reach a final purity value.
| Source of disagreement | Mechanism | Typical size of effect |
|---|---|---|
| Detection wavelength and gradient | Impurities absorb differently at 214, 220 and 280 nm; a shallower gradient resolves shoulders a steep one merges into the main peak | Tenths of a percent to a few percent in area-percent purity |
| Integration settings | Baseline placement, peak-width and threshold parameters decide whether a shoulder is a separate peak | Tenths of a percent |
| Reference standard | Content assays are relative to a standard whose own purity carries uncertainty | Several percent in content |
| Water and counter-ion | Hygroscopic powders gain mass between weighings; TFA or acetate is counted or excluded | Up to 15 to 25% in content if ignored |
| On-column artefacts | Old or reactive stationary phases oxidize methionine during the run | Up to 56% apparent oxidation in one reported setup |
| Unresolved impurities | Isobaric or co-eluting species, including D-isomers, hide under the main peak | Depends on the peptide; invisible to a single method |
The on-column figure comes from Baumans and colleagues in the Journal of Chromatography A in 2021, who found that a methionine-containing synthetic peptide showed up to 56% artefactual oxidation on a one-year-old column with a 180-minute gradient, and 0% on a different stationary phase, in results reproduced across laboratories. The impurity-correction point comes from Li and colleagues in 2021, who identified and quantified eighteen structurally related impurities totaling 31.1 mg/g in a synthetic oxytocin material used for an international comparison of laboratories' peptide-characterization competence, and from Stoppacher and colleagues in 2013, who showed that unaccounted impurities bias amino-acid-analysis value assignments. None of these effects is a laboratory error; each is a reason the method, column, wavelength and standard should be printed on the report.
How to weigh two reports on one lot
Weigh a report by five things before weighing its numbers: whether it is lot-matched to the vial, whether it names the method for each line, whether it tested finished units, whether it can be verified with the issuing laboratory, and what it did not test. Verification steps are detailed in how to verify a peptide lab report is real; the lot question in what a lot number is for.
When two reports agree within the expected method differences, the lot is well characterized and the manufacturer's process is confirmed. When they disagree, read the method lines before concluding anything. A purity gap of one or two percent between a 220 nm method and a 214 nm method, or between two gradients, is ordinary. A content gap of 15 percent is usually a counter-ion or water accounting difference, not a missing peptide, and the net peptide content vs purity article explains how to reconcile it. An identity disagreement, where one laboratory's mass does not match the sequence, is the one result that is not a method difference and should stop use of the lot until resolved. Validation vocabulary for judging whether a method is fit for purpose, including specificity, accuracy, precision and range, is set out in USP General Chapter <1225> and in ICH Q2(R2), which FDA adopted as guidance in 2024.
What US Prime Peptides does with the second laboratory
US Prime Peptides uses the independent report as the document of record for each lot. Every lot is tested by an independent US laboratory for identity by mass spectrometry, purity by HPLC, net peptide content, endotoxin, sterility and heavy metals by ICP-MS, and the lot-matched certificate is posted on the product page before purchase so a buyer can read the method lines first. The manufacturer's own release data remain on file and can be compared against the independent report when a customer asks, which is the comparison this article recommends.
Two practical notes follow. First, an independent report on identity and purity is routine; independent net content, sterility and endotoxin on finished units are the lines that most often go untested elsewhere, so check that they are present. Second, independence is not a substitute for scope: no standard panel measures chiral purity, aggregation or biological activity, and what a certificate of analysis does not test for lists those gaps so that a second report is read for what it is rather than for what it is assumed to be.
Frequently Asked Questions
Is a manufacturer's certificate of analysis enough for a research peptide?
It is a necessary document but a self-reported one, produced by the party that benefits from a pass, on its own equipment and against its own standard. An independent laboratory's lot-matched report on sealed units adds a separate measurement and tests the vial as distributed, which is why buyers should ask for both.
Why do two labs give different purity results for the same peptide?
Because HPLC purity is defined by the method: detection wavelength, gradient, column and integration settings all change how much of the trace is counted as impurity, and content assays depend on the reference standard and on whether water and counter-ions are subtracted. A USP multi-laboratory study of oxytocin found method choice, not laboratory competence, drove most of the spread.
What does ISO 17025 accreditation mean for a peptide testing lab?
ISO/IEC 17025:2017 is the international standard for the competence and impartiality of testing laboratories. Accreditation means an external body has assessed the laboratory's methods, equipment, staff and impartiality controls against that standard for a defined scope of tests, which can be checked, so a report from an accredited laboratory is auditable in a way an in-house certificate is not.
Which result matters more when a manufacturer COA and a third-party test disagree?
Compare the method lines first: a small purity gap or a content gap explained by counter-ion and water accounting is normal, and the report that tested finished units is usually the better guide to the vial itself. An identity mismatch is the exception; it is not a method difference and the lot should not be used until it is resolved.
Citations
- ISO. ISO/IEC 17025:2017 General requirements for the competence of testing and calibration laboratories. iso.org/standard/66912.html
- United States Pharmacopeia. General Chapter <1225> Validation of Compendial Procedures. USP-NF. doi.usp.org/USPNF/USPNF_M99945_04_01.html
- FDA. Q2(R2) Validation of Analytical Procedures: Guidance for Industry. 2024. fda.gov
- Li C, Bhavaraju S, Thibeault MP, et al. Survey of peptide quantification methods and comparison of their reproducibility: A case study using oxytocin. J Pharm Biomed Anal. 2019;166:105-112. PMID 30640042
- McCarthy D, Han Y, Carrick K, et al. Reference Standards to Support Quality of Synthetic Peptide Therapeutics. Pharm Res. 2023;40:1317-1328. PMID 36949371
- Melanson JE, Thibeault MP, Stocks BB, Leek DM, McRae G, Meija J. Purity assignment for peptide certified reference materials by combining qNMR and LC-MS/MS amino acid analysis results: application to angiotensin II. Anal Bioanal Chem. 2018;410:6719-6731. PMID 30143839
- Baumans F, Hanozin E, Baiwir D, et al. Liquid chromatography setup-dependent artefactual methionine oxidation of peptides: The importance of an adapted quality control process. J Chromatogr A. 2021;1654:462449. PMID 34399143
- Li M, Josephs RD, Daireaux A, et al. Structurally related peptide impurity identification and accurate quantification for synthetic oxytocin by liquid chromatography-high-resolution mass spectrometry. Anal Bioanal Chem. 2021;413:1861-1870. PMID 33479819
- Stoppacher N, Josephs RD, Daireaux A, Westwood S, Wielgosz RI. Impurity identification and determination for the peptide hormone angiotensin I by liquid chromatography-high-resolution tandem mass spectrometry and the metrological impact on value assignments by amino acid analysis. Anal Bioanal Chem. 2013;405:8039-8051. PMID 23708692
- Zolner WJ. Why do I need a Certificate of Analysis? Int J Pharm Compd. 2012;16:226-229. PMID 23050300
This article is for laboratory research reference only. US Prime Peptides products are supplied strictly for in vitro research. Not for human consumption.
Related research
- What a Lot Number Is For, and How to Match a Vial to Its Certificate
- What a Peptide Certificate of Analysis Does Not Test For
- How to Vet a Research Peptide Vendor: A 12-Point Checklist
- How to Read a Peptide Certificate of Analysis, Line by Line
- TFA Salt vs Acetate Salt: Why the Counter-Ion on a Peptide Matters
Compliance Notice: US Prime Peptides products are supplied strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution’s safety protocols and applicable laws.
